Personal longevity record · 2024 – 2026

Two years, one arc: from a fatty-liver scare to managing documented coronary plaque.

A reconstruction of every meaningful health decision — what was considered, the evidence weighed, and how each one evolved — mined from two years of chat history and stitched into a single evolving record.

Singapore · ~40 · APOE ε3/ε4 MTHFR C677T A/G ALDH2 AG · FADS1 GT Lp(a) low as of mid-2026

Core problem

Soft plaque

Jan 2026 CCTA: calcium score 0, non-calcified plaque in LAD + mid-RCA. Secondary-prevention-lite.

Current medication

Atorva 20 mg
+ Ezetimibe 10 mg

Ezetimibe added 2026-05-20. Target ApoB < 0.65 g/L.

Latest LDL-C

2.70 mmol/L

2026-05-13, on 20 mg pre-ezetimibe. From a pre-statin peak of 5.67.

Homocysteine

10.0 µmol/L

Recovered from a 22.2 crisis (Oct 2025) via daily B-complex + methylfolate.

The two-year arc

Order carries the argument here — each decision is a response to the one before it. ★ marks a pivot.

Biomarker trends

The numbers that drove the decisions. All values user-stated from labs; home-meter noise excluded.

Lipids & the statin experiment

LDL-C and ApoB against the medication timeline. The 2024 supplement-only dip never came; the statin did the work.

LDL-C (mmol/L) ApoB (g/L) ApoB target 0.65

The homocysteine crisis

A dropped daily B-vitamin plus an NMN up-dose, on an MTHFR background, drove a spike to 22.2 — then a daily methylfolate rescue.

Homocysteine (µmol/L) Doctor target < 9

Weight & the NAFLD cut

72 kg fatty-liver peak → 62 kg leanest (protein dropped to keep losing) → recomposition rebuild to ~68 kg.

Body weight (kg)

Body & biological aging

Two-timepoint reads. Visceral fat is the live worry; the epigenetic picture is mixed.

Visceral fat (DEXA)

227 → 370 g

+63% · 2014 → 2025

OMICmAge

33.7 → 29.9 yr

~10 yr younger than chrono

DunedinPACE

0.81 → 1.02

elite → average pace

Inflammation age

33 → 42 yr

+9 yr · lagging artifact?

The portfolio & supplement arc

Your operating manual, re-cut every ~6 months (v1→v4), and the rise and fall of every compound in it.

Stack size over time

Count of active supplements. The maximalist "avoid-statins" bulge, then the 2026 evidence-tiering prune as clinical levers (statin, ezetimibe, sleep) took over.

Four biannual versions

Each ~6-month cycle reframed the document. Recovered verbatim from the chats into portfolio/.

Every supplement's lifespan

Each bar runs from when a compound was added to when it was dropped (or now). Hover a bar for why it left. Grouped by system.

medication active experiment dropped / paused

Read the plans

The actual documents behind the arc, recovered verbatim from the chats. Pick a version to read it — newest is open by default.

Fourteen tracks

Each opens into its highlights. The full decision-by-decision reconstruction lives in tracks/.

For you to confirm

The reconstruction resolved most of the old open questions. These are the ones only you — or a future lab result — can close.

Trajectory — the live log

The reconstruction is history. From here, every decision, lab, experiment, and piece of research is captured as a dated entry (workflow in LOGGING.md) that rolls up into the next portfolio version — no more chat archaeology.

Open experiments

How this was built

119

conversations mined

634

dated decisions

1,127

data points

13

track narratives

Not medical advice. This is a personal record and analysis reconstructed from chat history. Values are as-stated at the time of each conversation and may be outdated. Decisions were made with, or are pending discussion with, actual clinicians.